Cargando…

Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis

BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Tsu-Chen, Hung, Lie Yee, Chen, Ying-Chun, Lo, Wei-Cheng, Lin, Chun Hung, Tam, Ka-Wai, Wu, Mei-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709169/ https://www.ncbi.nlm.nih.gov/pubmed/31335677 http://dx.doi.org/10.1097/MD.0000000000016311

Ejemplares similares

Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis
por: Hsu, Yun‐Shiuan O., et al.
Publicado: (2019)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
por: Park, Seokwoo, et al.
Publicado: (2022)

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease
por: Nata, Naowanit, et al.
Publicado: (2023)

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
por: Peng, Yueh-Lung, et al.
Publicado: (2020)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis
por: Zheng, Yanqun, et al.
Publicado: (2022)

Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis
por: Liu, Xuzhong, et al.
Publicado: (2018)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Association of Angiopoietin-2 with Renal Outcome in Chronic Kidney Disease
por: Tsai, Yi-Chun, et al.
Publicado: (2014)

The Incidence of Contrast-Induced Nephropathy and the Need of Dialysis in Patients Receiving Angiography: A Systematic Review and Meta-Analysis
por: Wu, Mei-Yi, et al.
Publicado: (2022)

Effect of Statins on Renal Function in Chronic Kidney Disease Patients
por: Hu, Ping-Jen, et al.
Publicado: (2018)

Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease
por: Chen, Szu-Chia, et al.
Publicado: (2013)

Aging is associated with slower renal progression in patients with chronic kidney disease
por: Yeh, Chia-Tse, et al.
Publicado: (2021)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

The interaction between fluid status and angiopoietin-2 in adverse renal outcomes of chronic kidney disease
por: Tsai, Yi-Chun, et al.
Publicado: (2017)

Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Cuenca, John A., et al.
Publicado: (2019)

Is Fluid Overload More Important than Diabetes in Renal Progression in Late Chronic Kidney Disease?
por: Tsai, Yi-Chun, et al.
Publicado: (2013)

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
por: Kim, Sang-Hyon, et al.
Publicado: (2020)

Glycosuria and Renal Outcomes in Patients with Nondiabetic Advanced Chronic Kidney Disease
por: Hung, Chi-Chih, et al.
Publicado: (2016)

Association of Renal Elasticity and Renal Function Progression in Patients with Chronic Kidney Disease Evaluated by Real-Time Ultrasound Elastography
por: Lin, Hugo You-Hsien, et al.
Publicado: (2017)

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease
por: Wu, Mei-Yi, et al.
Publicado: (2017)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Left Atrial Diameter and Albumin with Renal Outcomes in Chronic Kidney Disease
por: Chen, Szu-Chia, et al.
Publicado: (2013)

Association of hsCRP, White Blood Cell Count and Ferritin with Renal Outcome in Chronic Kidney Disease Patients
por: Tsai, Yi-Chun, et al.
Publicado: (2012)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
por: ZHANG, MEI, et al.
Publicado: (2014)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease
por: Wang, Hsiao-Han, et al.
Publicado: (2013)

Hyponatremia is Associated with Fluid Imbalance and Adverse Renal Outcome in Chronic Kidney Disease Patients Treated with Diuretics
por: Lim, Lee Moay, et al.
Publicado: (2016)

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy
por: He, Li, et al.
Publicado: (2017)

Low serum calcium is associated with poor renal outcomes in chronic kidney disease stages 3–4 patients
por: Lim, Lee-Moay, et al.
Publicado: (2014)

Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3–5
por: Kuo, I-Ching, et al.
Publicado: (2020)

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Do demographic factors and a health-promoting lifestyle influence the self-rated health of college nursing students?
por: CHOW, Susan Ka Yee, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6s6nonqttsrfe0sjhroki79br8